Phase 1, Dose Escalation Study Of CP-751,871 In Combination With Cisplatin And Gemcitabine In Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer.

Trial Profile

Phase 1, Dose Escalation Study Of CP-751,871 In Combination With Cisplatin And Gemcitabine In Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Feb 2013

At a glance

  • Drugs Figitumumab (Primary) ; Cisplatin; Gemcitabine; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 12 Feb 2010 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.
    • 12 Feb 2010 Actual patient number (45) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top